Tumor-associated macrophage polarization in the inflammatory tumor microenvironment
Open accessThe DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Abstract
The chronic inflammation of tumor continues to recruit TAMs (tumor−associated macrophages) to the TME (tumor microenvironment) and promote polarization. Pro-inflammatory signals polarize macrophages to the M1 phenotype to enhance inflammation against pathogens. Tumor inflammatory development changes the pro-inflammatory response to an anti-inflammatory response, resulting in the alteration of macrophages from M1 to M2 to promote tumor progression. Additionally, hypoxia activates HIF (hypoxia-inducible factors) in the TME, which reprograms macrophages to the M2 phenotype to support tumor development. Here, we discuss the factors that drive phenotypic changes in TAMs in the inflammatory TME, which will help in the development of cancer immunotherapy of macrophages.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both HIF-1α or HIF-2α expression in TAMs have been associated with tumor progression and/or poor prognosis in multiple tumor types, whereas lack of HIF-1α or HIF-2α in TAMs decreases metastasis, cell proliferation, and expression of pro-inflammatory cytokines such as IL-6 [73–76].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [74]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both HIF-1α or HIF-2α expression in TAMs have been associated with tumor progression and/or poor prognosis in multiple tumor types, whereas lack of HIF-1α or HIF-2α in TAMs decreases metastasis, cell proliferation, and expression of pro-inflammatory cytokines such as IL-6 [73–76].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [74]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
RETRACTED: FoxP3 Acts as a Cotranscription Factor with STAT3 in Tumor-Induced Regulatory T Cells
Hossain, D. M. S., Panda, A. K., Manna, A., Mohanty, S., Bhattacharjee, P., Bhattacharyya, S., Saha, T., Chakraborty, S., Kar, R. K., Das, T., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.11.005 · Cited by 120
RetractedWu, J., Zhang, J., Shen, B., Yin, K., Xu, J., Gao, W., & Zhang, L. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0229-3 · Cited by 117 · cited 1×
“For example, when TAMs are cocultured with hepatoma cells, macrophage-derived IL-6 and IL-8 activate JAK kinase, which phosphorylates STAT3 activating STAT3 signaling in tumor cells and promotes the epithelial mesenchymal transition(EMT), thus enhancing tumor invasion and metastasis (33, 34).”
BackgroundRetractedMyeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753 · cited 2×
“MDSCs also express high levels of arginase-1, which promote macrophage polarization and contribute to immune suppression (8, 43, 44).”
BackgroundProtective and pathogenic functions of macrophage subsets
Murray, P. J., & Wynn, T. A. (2011) · Nature Reviews Immunology · doi:10.1038/nri3073 · Cited by 5,269 · cited 1×
“But the chronic inflammation leads to the production of antiinflammatory signals and the transition of macrophages from the M1 to anti-inflammatory M2 phenotype to prevent excess inflammation from occurring (14).”
BackgroundIL‐6 in inflammation, immunity, and disease
Tanaka, T., Narazaki, M., & Kishimoto, T. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016295 · Cited by 5,046 · cited 1×
“In inflammatory TME, IL-6 secreted by TAMs resulting in a vicious cycle that further promote macrophages polarization to TAMS and increase IL-6 expression which can lead to a smoldering inflammatory state, and enhance tumor cell metastasis (46, 59).”
BackgroundTumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033 · cited 1×
“Clinical studies indicated that single-agent carlumab only temporarily repressed serum CCL2, resulting in no significant antitumor effects (76).”
BackgroundTargeting the IL-6/JAK/STAT3 signalling axis in cancer
Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110 · cited 1×
“IL-6 acts on IL-6R/gp130 receptors and active STAT3 signaling which can promote epithelial-mesenchymal transition (EMT), angiogenesis and immunosuppression in cancers (61).”
BackgroundFunctional Polarization of Tumour-Associated Macrophages by Tumour-Derived Lactic Acid
Colegio, O. R., Chu, N.-Q., Szabo, A. L., Chu, T., Rhebergen, A. M., Jairam, V., Cyrus, N., Brokowski, C. E., Eisenbarth, S. C., Phillips, G. M., et al. (2014) · Nature · doi:10.1038/nature13490 · Cited by 3,046 · cited 1×
“It was found that coculturing macrophages with tumor cells increased HIF-1 and VEGF expression, which induced the dysregulation of arginase and Fizz1, and this was correlated with a gene signature found in alternatively activated macrophages that promote tumor development (9, 32).”
BackgroundInflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,792
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
Targeting macrophages: therapeutic approaches in cancer
Cassetta, L., & Pollard, J. W. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.169 · Cited by 2,048
LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells
Brand, A., Singer, K., Koehl, G. E., Kolitzus, M., Schoenhammer, G., Thiel, A., Matos, C., Bruss, C., Klobuch, S., Peter, K., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.08.011 · Cited by 2,039
Tumor-Associated Macrophages in Tumor Immunity
Pan, Y., Yu, Y., Wang, X., & Zhang, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583084 · Cited by 1,872 · cited 2×
“MDSCs can suppress the immune response by abnormally regulating STAT3 to promote anti-inflammatory (M2like) macrophage polarization (31, 43).”
BackgroundMacrophage Polarization States in the Tumor Microenvironment
Boutilier, A. J., & Elsawa, S. F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136995 · Cited by 1,631 · cited 3×
“MDSCs also express high levels of arginase-1, which promote macrophage polarization and contribute to immune suppression (8, 43, 44).”
BackgroundHuman chimeric antigen receptor macrophages for cancer immunotherapy
Klichinsky, M., Ruella, M., Shestova, O., Lu, X. M., Best, A., Zeeman, M., Schmierer, M., Gabrusiewicz, K., Anderson, N. R., Petty, N. E., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0462-y · Cited by 1,495 · cited 1×
“It was found that CARMs encoding the CD3z intracellular domain can target the tumor antigen mesothelin or HER2 and kill antigen-positive solid tumor cells (93, 94).”
BackgroundFujiwara, N., & Kobayashi, K. (2005) · Current Drug Target -Inflammation & Allergy · doi:10.2174/1568010054022024 · Cited by 1,420 · cited 2×
“activate macrophages to resolve the inflammatory process (4).”
BackgroundRole of Human Macrophage Polarization in Inflammation during Infectious Diseases
Atri, C., Guerfali, F. Z., & Laouini, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061801 · Cited by 1,290
Altered macrophage differentiation and immune dysfunction in tumor development
Sica, A., & Bronte, V. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31422 · Cited by 1,238 · cited 1×
“tumor advanced state, more M2 macrophages are found, suggesting a dynamic switch from the M1 to the M2 phenotype (19).”
BackgroundCentral Role for G Protein-Coupled Phosphoinositide 3-Kinase γ in Inflammation
Hirsch, E., Katanaev, V. L., Garlanda, C., Azzolino, O., Pirola, L., Silengo, L., Sozzani, S., Mantovani, A., Altruda, F., & Wymann, M. P. (2000) · Science · doi:10.1126/science.287.5455.1049 · Cited by 1,209 · cited 1×
“PI3Kg inhibitors can alter macrophages toward proinflammatory phenotype and block recruitment of macrophages and neutrophils from peripheral blood (88, 89).”
BackgroundPI3Kγ is a molecular switch that controls immune suppression
Kaneda, M. M., Messer, K. S., Ralainirina, N., Li, H., Leem, C. J., Gorjestani, S., Woo, G., Nguyen, A. V., Figueiredo, C. C., Foubert, P., et al. (2016) · Nature · doi:10.1038/nature19834 · Cited by 1,173
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
Advani, R., Flinn, I., Popplewell, L., Forero, A., Bartlett, N. L., Ghosh, N., Kline, J., Roschewski, M., LaCasce, A., Collins, G. P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1807315 · Cited by 1,126 · cited 1×
“Hu5F9-G4 has been used in clinical trials to treat solid tumors and various hematological malignancies (82).”
MethodTumor-associated macrophages: an accomplice in solid tumor progression
Chen, Y., Song, Y., Du, W., Gong, L., Chang, H., & Zou, Z. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0568-z · Cited by 1,096
Self-citationThe inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages.
Allavena, P., Sica, A., Solinas, G., Porta, C., & Mantovani, A. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.07.004 · Cited by 1,044
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
Cannarile, M. A., Weisser, M., Jacob, W., Jegg, A.-M., Ries, C. H., & Rüttinger, D. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0257-y · Cited by 1,020
Ruffell, B., Chang-Strachan, D., Chan, V., Rosenbusch, A., Ho, C. M. T., Pryer, N., Daniel, D., Hwang, E. S., Rugo, H. S., & Coussens, L. M. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.006 · Cited by 1,008 · cited 1×
“It could improve chemotherapybyblocking IL-10 receptor to enhance primary tumor response in breast cancer with paclitaxel and carboplatin treatment (70).”
BackgroundM2b macrophage polarization and its roles in diseases
Wang, L.-X., Zhang, S.-X., Wu, H.-J., Rong, X.-L., & Guo, J. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.3ru1018-378rr · Cited by 884 · cited 1×
“IL‐10 induces the TAMM2 polarization that further secrete high IL‐10, IL‐6, TGF‐b, which can promoting fibrosis and enhance tumor growth (65, 66).”
BackgroundHume, D. A., & MacDonald, K. P. A. (2012) · Blood · doi:10.1182/blood-2011-09-379214 · Cited by 763
Macrophages in inflammation, repair and regeneration
Oishi, Y., & Manabe, I. (2018) · International Immunology · doi:10.1093/intimm/dxy054 · Cited by 734 · cited 3×
“Macrophages residing away from vessels in an environment of chronic hypoxia and a high concentration of lactate are induced to polarize to the M2 type (Figure 1) (1, 9).”
BackgroundCessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis
Bonapace, L., Coissieux, M.-M., Wyckoff, J., Mertz, K. D., Varga, Z., Junt, T., & Bentires-Alj, M. (2014) · Nature · doi:10.1038/nature13862 · Cited by 665 · cited 1×
“It was found that withdrawal of CCL2/CCR2 inhibitors might accelerate metastasis in breast cancer by dramatically releasing of monocytes which were trapped in the bone marrow (81).”
BackgroundDistribution of macrophage polarization markers in human atherosclerosis
Stöger, J. L., Gijbels, M. J. J., van der Velden, S., Manca, M., van der Loos, C. M., Biessen, E. A. L., Daemen, M. J. A. P., Lutgens, E., & de Winther, M. P. J. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.09.013 · Cited by 621 · cited 1×
“Under specific conditional stimulation and an unequal distribution of nutrients created by the TME, macrophages can be polarized to the M1 type (classically activated phenotype, with markers such as CD80/86) and M2 type (alternatively activated phenotype, with markers such as CD206, CD163, CD204, and stabilin-1), whic…”
BackgroundZheng, J. H., Nguyen, V. H., Jiang, S.-N., Park, S.-H., Tan, W., Hong, S. H., Shin, M. G., Chung, I.-J., Hong, Y., Bom, H.-S., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9537 · Cited by 588 · cited 1×
“Other TLR agonists have also been found to alter f M2 TAMs to pro-inflammatory M1 phenotype and promote tumor regression in mouse models (84).”
BackgroundZhu, X.-D., Zhang, J.-B., Zhuang, P.-Y., Zhu, H.-G., Zhang, W., Xiong, Y.-Q., Wu, W.-Z., Wang, L., Tang, Z.-Y., & Sun, H.-C. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.6521 · Cited by 556
The impact of hypoxia on tumor-associated macrophages
Henze, A.-T., & Mazzone, M. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84427 · Cited by 546 · cited 1×
“HIF activation in the hypoxic TME also induces the expression of a number of genes, such as VEGF or matrix metalloprotease 9 (MMP9), that affect macrophage polarization and drive tumor progression (24).”
BackgroundPerivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy
Hughes, R., Qian, B.-Z., Rowan, C., Muthana, M., Keklikoglou, I., Olson, O. C., Tazzyman, S., Danson, S., Addison, C., Clemons, M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3587 · Cited by 518 · cited 1×
“CXCL12 is a cancer-associated fibroblast derived factor which recruit CXCR4-expressing monocytes toTME and skew to M2-like macrophages to promote tumor growth (78).”
BackgroundMembrane Cholesterol Efflux Drives Tumor-Associated Macrophage Reprogramming and Tumor Progression
Goossens, P., Rodriguez-Vita, J., Etzerodt, A., Masse, M., Rastoin, O., Gouirand, V., Ulas, T., Papantonopoulou, O., Van Eck, M., Auphan-Anezin, N., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.02.016 · Cited by 502 · cited 1×
“Tumor cells also promote membrane cholesterol efflux induces IL-4mediated signaling in macrophages and alters their phenotype to promote tumor invasion and metastasis (30, 31).”
BackgroundBruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer
Gunderson, A. J., Kaneda, M. M., Tsujikawa, T., Nguyen, A. V., Affara, N. I., Ruffell, B., Gorjestani, S., Liudahl, S. M., Truitt, M., Olson, P., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0827 · Cited by 486 · cited 1×
“Inhibition of BTK in the pancreatic TME reduced tumor growth and enhanced antitumor activation (42).”
BackgroundLiu, C.-Y., Xu, J.-Y., Shi, X.-Y., Huang, W., Ruan, T.-Y., Xie, P., & Ding, J.-L. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.69 · Cited by 465
Bloch, O., Crane, C. A., Kaur, R., Safaee, M., Rutkowski, M. J., & Parsa, A. T. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3314 · Cited by 458
Yeung, O. W. H., Lo, C.-M., Ling, C.-C., Qi, X., Geng, W., Li, C.-X., Ng, K. T. P., Forbes, S. J., Guan, X.-Y., Poon, R. T. P., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.10.029 · Cited by 453 · cited 1×
“M2 macrophages further secrete antiinflammatory signals, such as IL-10 and TGF-b, to promote angiogenesis, remodeling, and immune suppression, which increase cancer cell proliferation, metastasis and resistance to therapy (15).”
BackgroundPartners in crime: neutrophils and monocytes/macrophages in inflammation and disease
Prame Kumar, K., Nicholls, A. J., & Wong, C. H. Y. (2018) · Cell and Tissue Research · doi:10.1007/s00441-017-2753-2 · Cited by 417
Pienta, K. J., Machiels, J.-P., Schrijvers, D., Alekseev, B., Shkolnik, M., Crabb, S. J., Li, S., Seetharam, S., Puchalski, T. A., Takimoto, C., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-012-9869-8 · Cited by 412 · cited 1×
“For example, an anti-CCL2 antibody, carlumab (CNTO888), can inhibitor macrophage infiltration to the tumor in mice, which has been applied in clinical trials to treat solid tumors and metastatic castrate-resistant prostate cancer (75).”
MethodOvarian Cancer Cells Polarize Macrophages Toward A Tumor-Associated Phenotype
Hagemann, T., Wilson, J., Burke, F., Kulbe, H., Li, N. F., Plüddemann, A., Charles, K., Gordon, S., & Balkwill, F. R. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.8.5023 · Cited by 411 · cited 1×
“Moreover, several studies in murine and human tumors also observed a “mixed” macrophage phenotype in the TME, and the phenotype of macrophages also differs from tumor to tumor or within different areas of the same tumor (20, 21), and macrophages in an advanced state of tumors show a more dominant M2 marker expression…”
BackgroundCapece, D., Fischietti, M., Verzella, D., Gaggiano, A., Cicciarelli, G., Tessitore, A., Zazzeroni, F., & Alesse, E. (2013) · BioMed Research International · doi:10.1155/2013/187204 · Cited by 408
Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers
Larionova, I., Tuguzbaeva, G., Ponomaryova, A., Stakheyeva, M., Cherdyntseva, N., Pavlov, V., Choinzonov, E., & Kzhyshkowska, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.566511 · Cited by 392 · cited 2×
“Moreover, several studies in murine and human tumors also observed a “mixed” macrophage phenotype in the TME, and the phenotype of macrophages also differs from tumor to tumor or within different areas of the same tumor (20, 21), and macrophages in an advanced state of tumors show a more dominant M2 marker expression…”
BackgroundLi, L., Yu, R., Cai, T., Chen, Z., Lan, M., Zou, T., Wang, B., Wang, Q., Zhao, Y., & Cai, Y. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106939 · Cited by 381 · cited 1×
“was found that IL-6 was a risk factor that highly expressed in chronic inflammatory tumor tissue that lead to poor prognosis (58).”
BackgroundSchmid, M. C., Avraamides, C. J., Dippold, H. C., Franco, I., Foubert, P., Ellies, L. G., Acevedo, L. M., Manglicmot, J. R. E., Song, X., Wrasidlo, W., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.016 · Cited by 378
A Transgenic Mouse Model of Inducible Macrophage Depletion
Goren, I., Allmann, N., Yogev, N., Schürmann, C., Linke, A., Holdener, M., Waisman, A., Pfeilschifter, J., & Frank, S. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.081002 · Cited by 361
Liu, C., Chikina, M., Deshpande, R., Menk, A. V., Wang, T., Tabib, T., Brunazzi, E. A., Vignali, K. M., Sun, M., Stolz, D. B., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.06.017 · Cited by 345
Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression
Kaneda, M. M., Cappello, P., Nguyen, A. V., Ralainirina, N., Hardamon, C. R., Foubert, P., Schmid, M. C., Sun, P., Mose, E., Bouvet, M., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1346 · Cited by 326
CCL2/CCR2 signaling in cancer pathogenesis
Hao, Q., Vadgama, J. V., & Wang, P. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00589-8 · Cited by 315
PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer
Yaghoubi, N., Soltani, A., Ghazvini, K., Hassanian, S. M., & Hashemy, S. I. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.11.105 · Cited by 299 · cited 8×
“TAMs expressing the checkpoint molecule PD-L1 negatively regulate the phagocytic ability of TAMs and suppress cytotoxic T-cell immunity against tumor cells.”
BackgroundInfluentialZhang, W., Liu, L., Su, H., Liu, Q., Shen, J., Dai, H., Zheng, W., Lu, Y., Zhang, W., Bei, Y., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0578-3 · Cited by 291 · cited 1×
“It was found that CARMs encoding the CD3z intracellular domain can target the tumor antigen mesothelin or HER2 and kill antigen-positive solid tumor cells (93, 94).”
BackgroundTumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies
Cervantes-Villagrana, R. D., Albores-García, D., Cervantes-Villagrana, A. R., & García-Acevez, S. J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0205-z · Cited by 290
Petrova, P. S., Viller, N. N., Wong, M., Pang, X., Lin, G. H. Y., Dodge, K., Chai, V., Chen, H., Lee, V., House, V., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1700 · Cited by 278
TNF Counterbalances the Emergence of M2 Tumor Macrophages
Kratochvill, F., Neale, G., Haverkamp, J. M., Van de Velde, L.-A., Smith, A. M., Kawauchi, D., McEvoy, J., Roussel, M. F., Dyer, M. A., Qualls, J. E., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.033 · Cited by 277 · cited 1×
“Other cytokines, such as myeloid differentiation primary response 88 (MyD88), can also inhibit M2 gene expression in TAMs, leading to an M1 phenotype (8, 72).”
BackgroundTumor-Associated Macrophages Enhance Tumor Hypoxia and Aerobic Glycolysis
Jeong, H., Kim, S., Hong, B.-J., Lee, C.-J., Kim, Y.-E., Bok, S., Oh, J.-M., Gwak, S.-H., Yoo, M. Y., Lee, M. S., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2545 · Cited by 268
Lim, S.-O., Li, C.-W., Xia, W., Lee, H.-H., Chang, S.-S., Shen, J., Hsu, J. L., Raftery, D., Djukovic, D., Gu, H., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2478 · Cited by 266 · cited 1×
“Hypoxic tumor cells also produce high amounts of lactate and HIF to polarize macrophages to the M2 phenotype to block effective antitumor immune responses by inhibiting tumor surveillance by T and NK cells (9, 27, 28).”
BackgroundPolarizing Macrophages In Vitro
Huang, X., Li, Y., Fu, M., & Xin, H.-B. (2018) · Methods in Molecular Biology · doi:10.1007/978-1-4939-7837-3_12 · Cited by 265 · cited 1×
“IL‐10 induces the TAMM2 polarization that further secrete high IL‐10, IL‐6, TGF‐b, which can promoting fibrosis and enhance tumor growth (65, 66).”
BackgroundCancer cell and macrophage cross-talk in the tumor microenvironment
Dehne, N., Mora, J., Namgaladze, D., Weigert, A., & Brüne, B. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.04.007 · Cited by 263 · cited 10×
“As mentioned before, The chronic inflammation of tumors continue to cause pro-and antiinflammatory response occurring, result in sustained polarization macrophages from the M1 to M2 type in the TME (Figure 2) (9).”
BackgroundInfluentialTsai, C.-S., Chen, F.-H., Wang, C.-C., Huang, H.-L., Jung, S.-M., Wu, C.-J., Lee, C.-C., McBride, W. H., Chiang, C.-S., & Hong, J.-H. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.01.041 · Cited by 257 · cited 1×
“Moreover, several studies in murine and human tumors also observed a “mixed” macrophage phenotype in the TME, and the phenotype of macrophages also differs from tumor to tumor or within different areas of the same tumor (20, 21), and macrophages in an advanced state of tumors show a more dominant M2 marker expression…”
BackgroundZhou, J., Ding, T., Pan, W., Zhu, L., Li, L., & Zheng, L. (2009) · International Journal of Cancer · doi:10.1002/ijc.24556 · Cited by 256 · cited 1×
“It was also found thatmacrophages exposed to tumor culture supernatants secretingmore IL-10 thatmay trigger a rise of the intratumoral forkhead/wingedhelix scurfy (FoxP3)Tregspopulation, which are associated with HCC aggressive (71).”
BackgroundKuang, D.-M., Wu, Y., Chen, N., Cheng, J., Zhuang, S.-M., & Zheng, L. (2007) · Blood · doi:10.1182/blood-2007-01-068031 · Cited by 256
Parker, K. H., Sinha, P., Horn, L. A., Clements, V. K., Yang, H., Li, J., Tracey, K. J., & Ostrand-Rosenberg, S. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2347 · Cited by 241 · cited 1×
“MDSCs also express high levels of arginase-1, which promote macrophage polarization and contribute to immune suppression (8, 43, 44).”
BackgroundFU, X.-T., DAI, Z., SONG, K., ZHANG, Z.-J., ZHOU, Z.-J., ZHOU, S.-L., ZHAO, Y.-M., XIAO, Y.-S., SUN, Q.-M., DING, Z.-B., et al. (2015) · International Journal of Oncology · doi:10.3892/ijo.2014.2761 · Cited by 230
Dan, H., Liu, S., Liu, J., Liu, D., Yin, F., Wei, Z., Wang, J., Zhou, Y., Jiang, L., Ji, N., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12644 · Cited by 218
Kellum, J. A., Song, M., & Li, J. (2004) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00564.2003 · Cited by 210
BMP4 Induces M2 Macrophage Polarization and Favors Tumor Progression in Bladder Cancer
Martínez, V. G., Rubio, C., Martínez-Fernández, M., Segovia, C., López-Calderón, F., Garín, M. I., Teijeira, A., Munera-Maravilla, E., Varas, A., Sacedón, R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1004 · Cited by 210
Chen, X., Pan, X., Zhang, W., Guo, H., Cheng, S., He, Q., Yang, B., & Ding, L. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.09.006 · Cited by 197
Zhang, W., Liu, Y., Yan, Z., Yang, H., Sun, W., Yao, Y., Chen, Y., & Jiang, R. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000285 · Cited by 173 · cited 1×
“showed that IL-6 promotes PD-L1 expression in monocytes and macrophages through JAK2/STAT1 and JAK2/STAT3/c-MYC signaling and induces immunosuppression in an orthotopic tumor transplantation model (63).”
BackgroundSalvagno, C., Ciampricotti, M., Tuit, S., Hau, C.-S., van Weverwijk, A., Coffelt, S. B., Kersten, K., Vrijland, K., Kos, K., Ulas, T., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0298-1 · Cited by 168
Targeting tumor-associated macrophages as an antitumor strategy
Cheng, N., Bai, X., Shu, Y., Ahmad, O., & Shen, P. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114354 · Cited by 161 · cited 2×
“Other CXCR4 antagonist, such as LY2510924 (CXCR4 antagonist peptide) also use in clinical trials for treating solid tumors (74, 79).”
BackgroundWang, Y.-C., Wang, X., Yu, J., Ma, F., Li, Z., Zhou, Y., Zeng, S., Ma, X., Li, Y.-R., Neal, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23164-2 · Cited by 157
Roles of CCL2-CCR2 Axis in the Tumor Microenvironment
Kadomoto, S., Izumi, K., & Mizokami, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168530 · Cited by 145
Weitzenfeld, P., & Ben‐Baruch, A. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.10.006 · Cited by 143
Huber, R., Meier, B., Otsuka, A., Fenini, G., Satoh, T., Gehrke, S., Widmer, D., Levesque, M. P., Mangana, J., Kerl, K., et al. (2016) · Scientific Reports · doi:10.1038/srep29914 · Cited by 139 · cited 2×
“For example, HIF-1a in hypoxic melanoma cells induced translocation and secretion of IL-10, which induced macrophage activation to the alternative M2 phenotype (13).”
BackgroundTargeting Innate Immunity in Cancer Therapy
Rameshbabu, S., Labadie, B. W., Argulian, A., & Patnaik, A. (2021) · Vaccines · doi:10.3390/vaccines9020138 · Cited by 129
Grossman, J. G., Nywening, T. M., Belt, B. A., Panni, R. Z., Krasnick, B. A., DeNardo, D. G., Hawkins, W. G., Goedegebuure, S. P., Linehan, D. C., & Fields, R. C. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1470729 · Cited by 123 · cited 1×
“CCL2 recruit CCR2+ inflammatory monocytes from the bone marrow to the peripheral blood that lead to cancer metastases and poor clinical outcomes (50).”
BackgroundEnhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers
Moisan, F., Francisco, E. B., Brozovic, A., Duran, G. E., Wang, Y. C., Chaturvedi, S., Seetharam, S., Snyder, L. A., Doshi, P., & Sikic, B. I. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.03.016 · Cited by 118 · cited 1×
“However, combination of carlumab with several conventional chemotherapy regimens such as paclitaxel and carboplatin, significantly enhance the antitumor response (77) Also, inhibition CXCR4‐CXCL12 signaling can more specifically promote TAM exclusion.”
BackgroundTumor-promoting macrophages prevail in malignant ascites of advanced gastric cancer
Eum, H. H., Kwon, M., Ryu, D., Jo, A., Chung, W., Kim, N., Hong, Y., Son, D., Kim, S. T., Lee, J., et al. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00538-y · Cited by 110
The Role of Tumor Associated Macrophages in Hepatocellular Carcinoma
Huang, Y., Ge, W., Zhou, J., Gao, B., Qian, X., & Wang, W. (2021) · Journal of Cancer · doi:10.7150/jca.51346 · Cited by 110
Liu, R., Yuan, W., Zeng, Q., Chan, K., Xiao, C., Zhao, X., Chen, M., Ouyang, F., Chen, D., Zheng, L., et al. (2015) · Hepatology · doi:10.1002/hep.28020 · Cited by 106 · cited 4×
“Inflammatory interleukin-17-positive (IL-171) T cells can recruit and promote maturation of chemokine receptor 3–positive (CXCR3) B cells, which induce M2b macrophage polarization in human HCC (41).”
BackgroundInfluentialHan, I., Song, H.-O., & Ryu, J. (2020) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0008126 · Cited by 92 · cited 1×
“found that IL-6 induces M2 polarization and promotes proliferation of prostate cancer cells (62).”
BackgroundBenetti, A., Berenzi, A., Gambarotti, M., Garrafa, E., Gelati, M., Dessy, E., Portolani, N., Piardi, T., Giulini, S. M., Caruso, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1218 · Cited by 84 · cited 3×
“CCL2, C-C motif chemokine ligand 2; CCL5, C-C motif chemokine ligand 5; CCR2, C-C motif chemokine receptor 2; CXCR2, C-X-C chemokine receptor type 2;CSF-1,colony-stimulating factor-1; CSF-1R, Colony stimulating factor 1 receptor; CARMs, chimeric antigen receptor macrophages; EMT, epithelial mesenchymal transition; Fiz…”
BackgroundTargeting tumor‐associated macrophages: A potential treatment for solid tumors
Chen, Y., Jin, H., Song, Y., Huang, T., Cao, J., Tang, Q., & Zou, Z. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30139 · Cited by 82
Self-citationElsawa, S. F., Novak, A. J., Ziesmer, S. C., Almada, L. L., Hodge, L. S., Grote, D. M., Witzig, T. E., Fernandez-Zapico, M. E., & Ansell, S. M. (2011) · Blood · doi:10.1182/blood-2011-04-351742 · Cited by 81
Tumor‑associated macrophages in lung cancer: Friendly or evil? (Review)
Xu, F., Wei, Y., Tang, Z., Liu, B., & Dong, J. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11518 · Cited by 67
Current status of intralesional agents in treatment of malignant melanoma
Zawit, M., Swami, U., Awada, H. K., Arnouk, J., Milhem, M. M., & Zakharia, Y. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-491 · Cited by 47 · cited 1×
“Others TLR9 agonist, such as SD101 was also investigation along with PD-1 blockade in clinical trials to enhance therapeutic efficacy (74, 85).”
BackgroundSmall-Molecule CSF1R Inhibitors as Anticancer Agents
Xun, Q., Wang, Z., Hu, X., Ding, K., & Lu, X. (2019) · Current Medicinal Chemistry · doi:10.2174/1573394715666190618121649 · Cited by 43 · cited 1×
“In a transgenic mouse model, targeting TAMs by CSF-1R blockade enhanced the anticancer efficacy of platinum-based chemotherapies (56, 57).”
BackgroundYin, Z., Huang, J., Ma, T., Li, D., Wu, Z., Hou, B., & Jian, Z. (2017) · Europe PMC (PubMed Central) · Cited by 40
Function, Regulation and Biological Roles of PI3Kγ Variants
Nürnberg, B., & Beer-Hammer, S. (2019) · Biomolecules · doi:10.3390/biom9090427 · Cited by 40
Mustea, A., Braicu, E. I., Koensgen, D., Yuan, S., Sun, P., Stamatian, F. V., Lichtenegger, W., Chen, F. C.-K., Chekerov, R., & Sehouli, J. (2008) · Cytokine · doi:10.1016/j.cyto.2008.10.019 · Cited by 37
Gemelli, C., Zanocco‐Marani, T., Bicciato, S., Mazza, E. M. C., Boraschi, D., Salsi, V., Zappavigna, V., Parenti, S., Selmi, T., Tagliafico, E., et al. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.01.021 · Cited by 36 · cited 1×
“By contact with its receptor, IL-10 can also activate the IL-10/STAT3 signaling pathway which skew macrophages to TAM M2 and promote high expression of various antiapoptosis, pro-tumorigenic and immunosuppression related genes (68).”
BackgroundChen, S., Qian, S., Zhang, L., Pan, X., Qu, F., Yu, Y., Gu, Z., Cui, X., & Haibo, S. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109139 · Cited by 31
Hypoxia-inducible Factor (HIF) in Hormone Signaling During Health and Disease
Dehne, N., Fuhrmann, D. C., & Brüne, B. (2013) · Cardiovascular & Hematological Agents in Medicinal Chemistry · doi:10.2174/1871525711311020008 · Cited by 17 · cited 1×
“Initiation of inflammation in the TME and pro-inflammatory cytokines, such as interleukin (IL)-1-b, IL-6, and IL-8, are produced by tumor cells, immune cells and nonmalignant cells that promote M1 polarization (12).”
Background
Cited by
Cancer immune evasion, immunoediting and intratumour heterogeneity
Roerden, M., & Spranger, S. (2025) · Nature Reviews Immunology · doi:10.1038/s41577-024-01111-8 · Cited by 265
Macrophage Polarization and the Regulation of Bone Immunity in Bone Homeostasis
Hu, K., Shang, Z., Yang, X., Zhang, Y., & Cao, L. (2023) · Journal of Inflammation Research · doi:10.2147/jir.s423819 · Cited by 192
Immunological factors linked to geographical variation in vaccine responses
van Dorst, M. M. A. R., Pyuza, J. J., Nkurunungi, G., Kullaya, V. I., Smits, H. H., Hogendoorn, P. C. W., Wammes, L. J., Everts, B., Elliott, A. M., Jochems, S. P., et al. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00941-2 · Cited by 97
Recent Advances in CAR-Based Solid Tumor Immunotherapy
Shin, M. H., Oh, E., Kim, Y. J., Nam, D.-H., Jeon, S., Yu, J. H., & Minn, D. (2023) · Cells · doi:10.3390/cells12121606 · Cited by 94
“As described earlier, CAR-M has phagocytic activity against solid tumors—similar to M1 macrophages in the TME [121,122,125].”
BackgroundInfluentialZhou, M., He, X., Mei, C., & Ou, C. (2023) · Biomarker Research · doi:10.1186/s40364-023-00538-w · Cited by 78
“Depending on their activation status, function, and secreted cytokines, macrophages can be categorized as one of two subtypes: M1 (pro-inflammatory, classically activated macrophages) and M2 (anti-inflammatory, alternatively activated macrophages) [15, 16].”
Background
Metadata
- Authors
- Zou, Z., Lin, H., Li, M., & Lin, B.
- Affiliations
- Hainan Medical University (CN)
- Corresponding author
- Li, Mengsen
- Lin, Bo
- ORCID
- Li, Mengsen
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2023-02-02
- Volume
- 13
- Pages
- 1103149-1103149
- ISSN
- 2234-943X (ISSN-L)
- PMC
- PMC9934926
- OpenAlex
- W4319793570
- Cited by
- 100
- References
- 95
- Citations by year
- 2026: 40 · 2025: 28 · 2024: 20 · 2023: 12
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (82060514, 31560243, 81660463, 81560450, [2019]22, 20168263, 81960519)
- Natural Science Foundation of Hainan Province (821RC1065, 822RC700, 2019CR204, 2019CXTD406, 20168263, 820RC634, JBGS202106)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Stress, Anesthesia, and Immune Response
- Keywords
- tumor-associated macrophages, macrophage polarization, tumor microenvironment, M1 macrophages, M2 macrophages, chronic inflammation, hypoxia, hypoxia-inducible factor, tumor progression, cancer immunotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

